Download 2017/3/17 Notice of establishment New Company, Denka

Notice of establishment New Company, Denka-KEW Genomics
Today, we announce that on February 15, 2017, KEW, Inc., a privately-held molecular diagnostics
company located in Cambridge, MA, USA and Denka, Co., Ltd. , a commercial manufacturing company of
chemical and life science products, located in Tokyo, Japan, officially entered into a joint venture,
Denka-KEW Genomics LLC (“DKGX”), for the purposes of providing comprehensive genomic profiling to
cancer patients in Japan and guiding therapeutic decisions based on individual patient tumor profiles.
“In October, 2015, KEW and Denka announced a strategic collaboration to establish the feasibility of
using CANCERPLEX in Japanese patients. Our recent publication in Genome Medicine (2016) is the
culmination of these efforts and serves as the basis for our establishing DKGX,” said Raju Kucherlapati,
Ph.D., Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and cofounder of KEW, Inc.
“The formation of DKGX represents a key milestone toward helping cancer patients in Japan. KEW is
honored to partner with Denka in this important mission,” said Tuan Ha-Ngoc, Executive Chairman, KEW,
Inc.
In the first half of 2017, DKGX will open a commercial clinical comprehensive genomic profiling
laboratory in Machida City, Tokyo. Under terms of the agreement, KEW will license its CANCERPLEX®
sequencing platform to DKGX. Additional terms of the agreement are not disclosed at this time.
About CANCERPLEX®
CANCERPLEX® is a comprehensive genomic profiling platform for sequencing over 400 cancer-related
genes, providing treatment decision support for cancer patients based on a patient’s tumor genomic
profile. Using industry-leading sequencing approaches and robust data analytics, a sample acceptance
rate of >95% and a rapid turn-around time of 7-10 business days, CANCERPLEX® provides therapeutic
options to >90% cancer patients profiled.
About Denka-KEW Genomics
Name
Denka-KEW Genomics
Paid-in Capital
Head Office
Nihonbashi Mitsui Tower,1-1,Nihonbashi-Muromachi
2-chome,Chuo-ku,Tokyo 103-8338,JAPAN
Laboratory
5-1, Asahi-machi 3-chome, Machida-shi, Tokyo 194-8560,JAPAN
10 million JPY
Capital contribution ratio
Denka 55% KEW 45%
Business Launch
April 2017
Directory
1
About KEW, Inc.
KEW, Inc. is a privately-held comprehensive genomic profiling company with headquarters in Cambridge,
MA, USA., dedicated to revolutionizing cancer care by providing therapeutic options based on an
individual patient’s tumor genomic profile. CANCERPLEX® is KEW’s flagship clinical product family for
sequencing and identifying applicable targeted therapies and clinical trials.
About Denka, Co. Ltd.
Denka Co. Ltd., is a public manufacturing and distribution company for a variety of chemical products,
including organic and inorganic materials, polymers, electronic materials and pharmaceuticals,
contributing to the quality of life and development of society for 100 years through innovations in
technology. Focusing on healthcare business sector as a key growth area, Denka is establishing its fifth
business division, "Life Innovation", to accelerate its growth.
2